scholarly journals Treating patients with advanced hepatocellular carcinoma and impaired liver function: Broadening the reach of anti‐cancer therapy

2021 ◽  
Author(s):  
Antonio D'Alessio ◽  
Claudia Angela Maria Fulgenzi
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cancer Therapy ◽  
Liver Function ◽  
Advanced Hepatocellular Carcinoma ◽  
Impaired Liver Function ◽  
Impaired Liver ◽  
Anti Cancer

scholarly journals Surgical treatment strategy for hepatocellular carcinoma in patients with impaired liver function: hepatic resection or radiofrequency ablation?

HPB ◽  
2018 ◽  
Vol 20 (3) ◽  
pp. 244-250 ◽  
Author(s):  
Takanobu Yamao ◽  
Katsunori Imai ◽  
Yo-ichi Yamashita ◽  
Takayoshi Kaida ◽  
Shigeki Nakagawa ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Surgical Treatment ◽  
Radiofrequency Ablation ◽  
Liver Function ◽  
Hepatic Resection ◽  
Treatment Strategy ◽  
Impaired Liver Function ◽  
Impaired Liver

Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2

2017 ◽  
Vol 35 (6) ◽  
pp. 589-597 ◽  
Author(s):  
Tadaaki Arizumi ◽  
Tomohiro Minami ◽  
Hirokazu Chishina ◽  
Masashi Kono ◽  
Masahiro Takita ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cancer ◽  
Liver Function ◽  
Transcatheter Arterial Chemoembolization ◽  
Time To Progression ◽  
Impaired Liver Function ◽  
Impaired Liver ◽  
Tace Treatment ◽  
Arterial Chemoembolization

Background: Transarterial chemoembolization (TACE) is recommended for patients with hepatocellular carcinoma (HCC) in Barcelona Clinic Liver Cancer (BCLC) stage B. However, because of the heterogeneity of HCC in BCLC stage B; various subclassification systems have been proposed to predict the prognosis of patients. Previously, we proposed the Kinki criteria for precise classification of HCC cases in BCLC stage B. In this study, we compared the time to TACE refractoriness in HCC patients with Kinki criteria substages B1 and B2-HCC. Summary: Between January 2006 and December 2013, 592 HCC patients (substage B1, n = 118; substage B2, n = 170) underwent TACE. Time to progression under TACE treatment was defined as the time to untreatable progression (TTUP). TTUP and changes in liver function were analyzed in patients with substages B1 and B2-HCC. The median TTUP was 25.7 months (95% CI 19.3-37.3) and 16.4 months (95% CI 13.1-20.2) in patients with substage B1-HCC and substage B2-HCC, respectively (p = 0.0050). In patients with substage B2-HCC, median Child-Pugh scores after the first TACE session was significantly different from those after third and fifth TACE sessions (first-third, p = 0.0020; first-fifth, p = 0.0008). Key Message: TACE refractoriness occurred earlier in patients with substage B2-HCC than those with substage B1-HCC; deterioration of liver function with repeated TACE was more obvious in HCC cases with stage-B1 tumor. Shorter TTUP and impaired liver function due to repeated TACE could be responsible for the shorter survival in patients with substage B2-HCC.

Hepatic resection of hepatocellular carcinoma in cirrhotic livers: Is it unjustified in impaired liver function?

Surgery ◽  
1996 ◽  
Vol 120 (1) ◽  
pp. 34-39 ◽  
Author(s):  
Cheng-Chung Wu ◽  
Willam-Lin Ho ◽  
Da-Cheng Yeh ◽  
Chi-Ren Huang ◽  
Tse-Jia Liu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Function ◽  
Hepatic Resection ◽  
Impaired Liver Function ◽  
Impaired Liver

Impaired liver function and long-term prognosis after hepatectomy for hepatocellular carcinoma

1995 ◽  
Vol 19 (3) ◽  
pp. 439-443 ◽  
Author(s):  
Motoshi Yasui ◽  
Akio Harada ◽  
Akihito Torii ◽  
Akimasa Nakao ◽  
Toshiaki Nonami ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Function ◽  
Impaired Liver Function ◽  
Impaired Liver ◽  
Long Term Prognosis
Sign in / Sign up

Export Citation Format

Share Document